Literature DB >> 21954409

Recent and currently emerging medical treatment options for the treatment of alcoholic hepatitis.

Gabriel L Reep1, Roger D Soloway.   

Abstract

Patients with severe alcoholic hepatitis (AH) need to be treated with specific treatment for better outcome. Currently available specific treatment modalities are use of corticosteroids or pentoxifylline. However, the response rate to these drugs is only about 50%-60%. Hence, there is an urgent need for better and more effective treatment options. Tumor necrosis factor plays an important role in the pathogenesis of AH. However, agents blocking the action of tumor necrosis factor have not been found to be effective. Rather the randomized studies evaluating these agents showed an adverse effect and more infections in treated patients. Critical role of tumor necrosis factor in hepatic regeneration explaining this contrast is discussed. Oxidative stress and inflammation derived from gut bacteria ate two main components in the pathogenesis of AH laying foundation for the role of antioxidants, probiotics, and antibiotics in the management of AH. This article reviews the current data and status of these newer agents for the treatment of AH. Of the various options available, Vitamin E and N-acetylcysteine (NAC) have shown great promise for clinical use as adjunct to corticosteroids. With these encouraging data, future well designed studies are suggested to assess Vitamin E and NAC before their routine use in clinical practice in the management of AH.

Entities:  

Keywords:  Alcoholic hepatitis; Antioxidants; Betaine; Etanercept; Granulocytapheresis; Infliximab; Probiotics; Rifaximin; Tumor necrosis factor-α inhibitors

Year:  2011        PMID: 21954409      PMCID: PMC3180606          DOI: 10.4254/wjh.v3.i8.211

Source DB:  PubMed          Journal:  World J Hepatol


  24 in total

Review 1.  Cytokines: overview.

Authors:  J J Maher
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

2.  Betaine resolves severe alcohol-induced hepatitis and steatosis following liver transplantation.

Authors:  Karim Samara; Chen Liu; Consuelo Soldevila-Pico; David R Nelson; Manal F Abdelmalek
Journal:  Dig Dis Sci       Date:  2006-07       Impact factor: 3.199

3.  Granulocytapheresis in the treatment of severe alcoholic hepatitis: a case series.

Authors:  Judith M Morris; Sheila Dickson; Margaret Neilson; Paul Hodgins; Ewan H Forrest
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-04       Impact factor: 2.566

Review 4.  Alcohol and oxidative liver injury.

Authors:  Aparajita Dey; Arthur I Cederbaum
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

5.  A randomized placebo controlled trial of vitamin E for alcoholic hepatitis.

Authors:  Esteban Mezey; James J Potter; Lynda Rennie-Tankersley; Juan Caballeria; Albert Pares
Journal:  J Hepatol       Date:  2004-01       Impact factor: 25.083

6.  A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis.

Authors:  Nicholas C Boetticher; Craig J Peine; Paul Kwo; Gary A Abrams; Tushar Patel; Bashar Aqel; Lisa Boardman; Gregory J Gores; William S Harmsen; Craig J McClain; Patrick S Kamath; Vijay H Shah
Journal:  Gastroenterology       Date:  2008-09-13       Impact factor: 22.682

7.  Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis.

Authors:  Vanessa Stadlbauer; Rajeshwar P Mookerjee; Stephen Hodges; Gavin A K Wright; Nathan A Davies; Rajiv Jalan
Journal:  J Hepatol       Date:  2008-03-25       Impact factor: 25.083

8.  Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study.

Authors:  Laurent Spahr; Laura Rubbia-Brandt; Jean-Loius Frossard; Emile Giostra; Anne-Laure Rougemont; Jérôme Pugin; Maria Fischer; Hanspeter Egger; Antoine Hadengue
Journal:  J Hepatol       Date:  2002-10       Impact factor: 25.083

9.  Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement.

Authors:  Agustín Albillos; Antonio de la Hera; Mónica González; Jose-Luis Moya; Jose-Luis Calleja; Jorge Monserrat; Luis Ruiz-del-Arbol; Melchor Alvarez-Mon
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

Review 10.  Neutrophil-mediated tissue injury in alcoholic hepatitis.

Authors:  Hartmut Jaeschke
Journal:  Alcohol       Date:  2002-05       Impact factor: 2.405

View more
  2 in total

Review 1.  Therapy for alcoholic liver disease.

Authors:  Maryconi M Jaurigue; Mitchell S Cappell
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

Review 2.  Molecular targets in the treatment of alcoholic hepatitis.

Authors:  Ashwin D Dhanda; Richard Wl Lee; Peter L Collins; C Anne McCune
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.